Rituximab in high-grade lymphoma

Seminars in Hematology

Volumn 47, Issue 2, 2010, Pages 148-155

  Zwick, Carsten ^a   Murawski, Niels ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; OXALIPLATIN; PLATINUM COMPLEX; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 77950330638     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.008     Document Type: Article

References (59)

1. McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484-1493.
2. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
3. Gianni A.M., Bregni M., Siena S., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997, 336:1290-1297.
4. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000, 18:3025-3030.
5. Verdonck L.F., van Putten W.L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995, 332:1045-1051.
6. Santini G., Salvagno L., Leoni P., et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998, 16:2796-2802.
7. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001, 93:22-30.
8. Kaiser U., Uebelacker I., Abel U., et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002, 20:4413-4419.
9. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor- prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
10. Martelli M., Gherlinzoni F., De Renzo A., et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003, 21:1255-1262.
11. Milpied N., Deconinck E., Gaillard F., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004, 350:1287-1295.
12. Betticher D.C., Martinelli G., Radford J.A., et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006, 17:1546-1552.
13. Olivieri A., Santini G., Patti C., et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol 2005, 16:1941-1948.
14. Vitolo U., Liberati A.M., Cabras M.G., et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Haematologica 2005, 90:793-801.
15. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
16. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
17. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
18. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
19. Pfreundschuh M., Truemper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
20. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
21. Manches O., Lui G., Chaperot L., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
22. Van der Kolk L.E., Evers LM Omene C., et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002, 16:1735-1744.
23. Harjunpaa A., Junnikkala S., Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000, 51:634-641.
24. Dall'Ozzo S., Tartas S., Paintaud G., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64:4664-4669.
25. Golay J., Cittera E., Di Gaetano N., et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.
26. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669.
27. Schmitz R., Nickelsen M., Ziepert M., et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. ASH Annual Meeting Abstracts 2009, 22:404. 114.
28. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
29. Pfreundschuh M., Schubert J., Ziepert M., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
30. Cunningham D., Smith P., Mouncey P., et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma [abstract 8506]. J Clin Oncol 2009, 27:15s.
31. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
32. Reiser M., Wenger M., Nickenig C., et al. Serum levels and pharmacokinetics of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial [abstract]. J Clin Oncol 2006, 24:430s.
33. Poeschel V., Nickelsen M., Hänel M., et al. Dose-dense rituximab in combination with bi-weekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma: results of phase I/II and pharmacokinetic study of the German High-grade Non-Hodgkin Lymphoma Study Group. Blood 2006, 108:774a-775a.
34. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
35. Guglielmi C., Gomez F., Philip T., et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264-3269.
36. Cabanillas F., Hagemeister F.B., Bodey G.P., Freireich E.J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982, 60:693-697.
37. De Lord C., Newland A.C., Linch D.C., Vaughan H.B., Vaughan H.G. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol 1992, 10:81-86.
38. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71:117-122.
39. Soussain C., Souleau B., Gabarre J., et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999, 33:543-550.
40. Sweetenham J.W., Johnson P.W. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol 1994, 12:2766.
41. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994, 12:1169-1176.
42. Rodriguez M.A., Cabanillas F.C., Velasquez W., et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995, 13:1734-1741.
43. Wilson W.H., Bryant G., Bates S., et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993, 11:1573-1582.
44. Chao N.J., Rosenberg S.A., Horning S.J. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990, 76:1293-1298.
45. Cortelazzo S., Rambaldi A., Rossi A., et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001, 114:333-341.
46. Atta J., Chow K.U., Weidmann E., et al. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2007, 48:349-356.
47. Reiser M., Josting A., Dias W.P., et al. Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1999, 33:305-312.
48. Moskowitz C., Hamlin P.A., Horwitz S.M., et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy-confirmed abnormal interim restaging PET scan improves outcome of patients with advanced stage DLBCL [abstract]. Blood 2006, 108:161a.
49. Kewalramani T., Zelenetz A.D., Nimer S.D., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103:3684-3688.
50. Mey U.J., Orlopp K.S., Flieger D., et al. Dexamethasone, high-dose cytarabine and cisplatin in combination wirh rituximab as salvage treatment patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006, 24:593-600.
51. Vellenga E., van Putten W.L., 't Veer M.B., et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
52. Gisselbrecht C., Glass B., Mounier N., et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation [abstract]. J Clin Oncol 2009, 27:436s.
53. Glass B., Borgerding A., Ziepert M., et al. Outcome of elderly patients with DLBCL failing R-CHOP. The role of rituximab and high dose therapy in second line treatment. A retrospective analysis from the RICOVER 60 trial. [abstract]. ASH Annual Meeting Abstracts 2009, 22:3714. 114.
54. Martin A., Conde E., Arnan M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
55. El Gnaoui T., Dupuis J., Belhadj K., et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007, 18:1363-1368.
56. Van Oers M., Van Glabekke M., Baila L., Giurgia L., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract]. Am Soc Hematol 2008, 836.
57. Forstpointner R., Unterhalt M., Dreyling M., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with R-FCM in patients with refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008.
58. Ghielmini M., Schmitz S.F., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423.
59. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.